1. Introduction {#s0005}
===============

The fields of circadian biology and sleep-wake regulation have been closely intertwined for decades, with many studies investigating how the circadian clock regulates daily rhythms in sleep and wakefulness, and in turn how arousal levels in animals affect their circadian clocks. However, research investigating the cellular mechanisms underlying circadian rhythms and sleep-wake regulation has rarely been conducted in a coordinated fashion. Thus, it is noteworthy that many of the same molecular mechanisms are critical elements of both systems. For example, circadian and sleep-wake systems involve overlapping intracellular synaptic plasticity mechanisms (e.g., [@bib33]; [@bib260]; [@bib118]; [@bib4]). More recently, accumulating evidence supports both systems utilizing mechanisms that involve proteins (inter)acting within the extracellular synaptic space. This scenario parallels the well-documented involvement of both intracellular and extracellular protein interactions in learning- and addiction-associated synaptic plasticity (e.g., [@bib261]; [@bib284]; [@bib205]; [@bib1]; [@bib287]; [@bib63]). Based on these similarities, a unified review of the dynamic extracellular protein interactions involved in circadian rhythm and sleep-wake regulation seems warranted.

There is a rich literature on the neuroanatomy of the circadian and sleep-wake systems, as well as the neurotransmitters regulating both systems. There is also a great deal known about the intracellular signaling pathways and genetic underpinnings of the circadian system, while these aspects of the sleep-wake system are somewhat less clear. The extensive research focused on these critical aspects of both systems has greatly enhanced our understanding of the systems and their interactions, and there are many excellent reviews of these topics, some of which we reference in this review. Our goal here is to highlight extracellular mechanisms that complement the better-known intracellular processes underlying both regulatory systems, with a specific focus on those interacting with the extracellular matrix. With that goal in mind, we acknowledge that this review will skip over many elements central to the functioning of the two systems, and in so doing we do not mean to downplay their importance. Indeed, we believe that a complete understanding of both the circadian and sleep-wake systems and their interactions ultimately will depend on fully connecting the intracellular and the extracellular mechanisms to create a unified picture.

2. Background on the circadian rhythm and sleep-wake systems {#s0010}
============================================================

2.1. Circadian rhythms {#s0015}
----------------------

Endogenous circadian oscillators precisely orchestrate the daily behavioral and physiological rhythms of most organisms, while simultaneously maintaining proper phase and synchrony with the external environment. The preeminent circadian clock in mammals is located in the suprachiasmatic nucleus (SCN), a bilateral structure immediately above the optic chiasm that straddles the third ventricle. The SCN is not homogeneous; it can be divided into dorsal/shell vs. ventral/core regions based on differential expression of neuropeptides, ion channels, transporters, and receptors; amplitude and phase of clock gene expression rhythms; and afferent and efferent projections ([@bib182], [@bib270], [@bib178], [@bib108]), although this is likely a dramatic oversimplification of SCN organization ([@bib186]). Lesions of the SCN eliminate daily rhythms such as the sleep-wake rhythm, body temperature rhythm, and daily hormonal rhythms, while not affecting their overall expression level ([@bib182], [@bib177], [@bib183]). Conversely, transplanting fetal SCN tissue back into the brain after SCN lesions can restore circadian rhythms ([@bib55], [@bib146], [@bib225]). The SCN continues to generate 24 h rhythms in neuronal activity, neuropeptide secretion, and metabolism when isolated *in vitro* ([@bib89], [@bib248], [@bib222], [@bib109], [@bib90]). Together with many other lines of data, these results support the SCN's role as the master circadian clock.

The SCN circadian oscillator consists of a transcriptional-translational negative feedback loop (TTFL) involving a group of clock genes that includes *Period* (*Per*) *1* and *2*; *Cryptochrome* (*Cry*) *1* and *2*, *Brain and muscle Arnt-like-1* (*Bmal1)*, and *Clock*. BMAL1 and CLOCK proteins are transcriptional regulators that increase transcription of *Per* and *Cry* genes, the mRNAs for which are then translated into proteins that slowly accumulate in the cytoplasm. Once their levels increase sufficiently, PER and CRY proteins enter the nucleus, dimerize, and inhibit the activity of BMAL1/CLOCK, thus decreasing their own transcription. For more information on the complex inter-workings of the TTFL, see detailed reviews ([@bib85], [@bib108], [@bib30]). The TTFL is coupled to additional circadian oscillator gears, including a redox oscillator and a cell membrane oscillator that are thought to strengthen and stabilize the SCN circadian clock ([@bib90], [@bib176], [@bib108]). Although the individual cellular circadian oscillators are autonomous, intercellular coupling mechanisms within the SCN further strengthen the circadian clock, creating the dominant synchronizing signals for the rest of the organism ([@bib109], [@bib70]).

SCN clock phase is modulated by many inputs. However, the primary environmental synchronizer of the clock is light stimulation of the retina, which communicates with the SCN via the retinohypothalamic tract ([@bib233], [@bib184]). Photic stimulation triggers glutamate release from retinal ganglion cell synaptic terminals within the SCN. Glutamate activation of postsynaptic AMPA receptors (AMPARs) and NMDA receptors (NMDARs) depolarizes the neurons, increases intracellular Ca^2+^ levels, and activates intracellular signaling cascades ([@bib61], [@bib174], [@bib169]). When these events occur during the subjective nighttime, they trigger increases in the transcription and translation of circadian clock genes that result in a phase delay or phase advance of the clock depending on whether they occur during the early or late night, respectively. Conversely, if these events occur during the subjective day they have no effect on clock phase. Thus, the circadian clock exhibits time-dependent responses ([@bib169], [@bib37], [@bib45]). The initial phase-shifting events are thought to occur primarily in neurons in the ventral/core region of the SCN \[e.g., vasoactive intestinal polypeptide (VIP)-containing neurons\], which process and transmit the information to neurons in the dorsal/shell region of the SCN \[e.g. vasopressin (VP)-containing neurons\]. Cells in the dorsal/shell SCN subsequently generate signals to coordinate rhythmicity within the SCN and distribute rhythmic signals to the rest of the organism ([@bib193], [@bib3], [@bib240]).

While we know quite a bit about the intracellular gears of the circadian clock and the pathways mediating photic phase resetting, several pressing questions remain unanswered regarding SCN clock function. It is not fully understood how SCN cells couple and synchronize, and what regulates changes in these coupling and synchronizing processes. The full diversity of cell types within the SCN and their specific functions within the circadian clock are still being defined. Also, the mechanisms restricting photic phase-resetting responses to the night are also unclear. Extracellular mechanisms may provide answers to some of these questions.

2.2. Sleep-wake system {#s0020}
----------------------

Unlike the SCN circadian clock, the sleep-wake system is distributed across many brain regions, including the brainstem, midbrain, hypothalamus, thalamus, and cortex. Moreover, sleep is not a single phenomenon, but a complex mixture of different brain states. Sleep can be divided into distinct stages based on electroencephalogram (EEG) and electromyogram recordings, including slow wave sleep (SWS), characterized by high amplitude, low frequency brain waves, and rapid eye movement sleep (REMS), characterized by low amplitude, higher frequency EEG activity. Animals, including humans, cycle through the different sleep states in a species- and age-dependent frequency throughout the sleeping period ([@bib236]).

Although rapid cycling between sleep- and wake-like states can be observed within small regions such as cortical columns (e.g., [@bib227]; discussed in [@bib126]), the global brain circuitry and neurotransmitters contributing to regulating sleep is complex, and a thorough review is beyond the scope of this paper. Broadly speaking, the system can be divided into "wake-promoting" and "sleep-promoting" areas (keeping in mind that most of these areas are heterogeneous in their cellular composition, e.g., [@bib294]).

Monoaminergic wake-promoting areas include the locus coeruleus (LC), raphe nuclei, ventral tegmental area (VTA), tuberomammillary nucleus, parabrachial nucleus, pedunculopontine tegmental nucleus (PPT) and laterodorsal tegmental nucleus. Neurons in these areas, especially the cholinergic parabrachial nucleus and PPT neurons, project to the cholinergic basal forebrain, which in turn sends projections throughout the cortex. These neurons generate much of the alerting signals for the brain ([@bib236]). Another set of neurons critical for arousal are orexin-containing neurons in the lateral hypothalamus (LH). These LH neurons project to the thalamus as well as to sleep-promoting regions discussed below ([@bib36], [@bib152], [@bib194]). SWS-promoting areas include the ventrolateral preoptic (VLPO) and medial preoptic areas, the parafacial zone, and GABAergic neurons in the basal forebrain. Neurons in all of these areas promote sleep at least in part by inhibiting the activity of wake-promoting neurons ([@bib137], [@bib78], [@bib17]).

In addition to sleep-promoting neurons inhibiting the wake-promoting neurons mentioned above, REMS regulation involves the sublaterodorsal nucleus, which is activated by PPT/laterodorsal tegmental nucleus cholinergic signals as well as by the decrease in LC- and raphe-induced inhibition that occurs during SWS. The sublaterodorsal nucleus, along with two reticular nuclei, acts on the medulla to inhibit motor activity and on the ventrolateral periaqueductal gray to promote REMS ([@bib27]). For more detailed information on the neuroanatomy and neurochemistry of sleep, see several excellent reviews ([@bib236], [@bib81], [@bib65]).

As with the circadian system, there are still many outstanding questions regarding the sleep-wake system. Included among them are the distinct functions and mechanisms underlying SWS vs. REMS. Other questions include why regular cycling between different sleep states is important, and what are the mechanisms controlling these state changes. A possibility explored in this review is that mechanisms regulating sleep-wake and sleep state transitions, as well as the functional properties of sleep may involve extracellular processes. It will be important going forward to gain a better understanding of what triggers the different state transitions at both local and global levels, and how the regular cycling between sleep states enhances the restorative actions of sleep.

2.3. Circadian-sleep connection {#s0025}
-------------------------------

A conceptual model of how the daily sleep-wake cycle is generated invokes two distinct processes: a homeostatic "Process S" and a circadian clock-generated "Process C". Process S accumulates while an animal is awake, slowly increasing the drive to fall asleep. Process C, an alerting signal, waxes and wanes with the activity of the circadian clock. During the animal's active phase Process S and Process C increase in parallel, keeping the animal alert and active. However, as the day progresses Process C reaches its peak and starts to decline, while Process S continues to increase. Eventually, the sleep-promoting Process S overcomes the diminished alerting signal of Process C and the animal falls asleep. While the animal sleeps, Process S dissipates, and Process C, having reached is nadir, begins to increase. Once Process C reaches and surpasses Process S the animal awakens to begin a new cycle ([@bib22], [@bib23]). Although simplistic, this model succinctly illustrates the interactive nature of the two systems.

The circadian signal regulating sleep includes SCN efferents to the subparaventricular zone, which sends excitatory projections to the medial preoptic and dorsomedial hypothalamus, the latter of which sends additional excitatory projections to LH orexin neurons and to the LC ([@bib57], [@bib23]). Because SCN neuronal activity is higher in the day, the initial output from the SCN is thought to be inhibitory in nocturnal animals and excitatory in diurnal animals. Distinct from the circadian signals emanating from the SCN, there are distributed circadian influences on sleep. For example, the circadian clock gene *Bmal1* regulates the rhythmic production of histamine in wake-promoting tuberomammillary neurons. Selective *Bmal1* deletion in these neurons, rendering them arrhythmic, disrupts circadian sleep-wake rhythms without disrupting circadian rhythms overall ([@bib295]). Another circadian clock gene, *Rev-erbα*, regulates circadian dopamine production in the VTA ([@bib39]). There are also interesting data pointing to *Bmal1*-supported circadian rhythmicity specifically in muscle cells being important for normal sleep regulation ([@bib66]).

The nature of the homeostatic "Process S" is less clear, and likely encompasses multiple factors. Examples of postulated molecules include extracellular adenosine, which has been shown to increase during wake in parallel with higher metabolic activity and to decrease during sleep as metabolism wanes ([@bib18], [@bib110]); prostaglandin D~2~, which also accumulates during wake, activates DP1 receptors and increases extracellular adenosine levels ([@bib112]); and cytokines such as interleukin (IL)-1β and tumor necrosis factor (TNF)α ([@bib43]). Central to the concept of "Process S" is that sleep serves a restorative function that allows the brain to consolidate synaptic changes generated by previous events, replenish energy stores, and eliminate accumulated metabolic byproducts ([@bib139], [@bib41]).

While the interactions between Process C and S provide an elegant conceptual model of the interplay between these two systems, it provides little insight into the cellular mechanisms that regulate the cycling between different sleep states, between sleep and wakefulness, and between different phases of the circadian clock. Although the circadian and sleep-wake systems are quite distinct, it is noteworthy that they share many cellular processes. Relevant to this review, accumulating evidence supports both systems utilizing extracellular processes that overlap the synaptic mechanisms associated with learning, memory, and drug addiction. These extracellular mechanisms include changes in enzymatic activity, protein-protein interactions, cellular morphology involving the extracellular matrix (ECM), ECM-associated proteins, cell-adhesion molecules, cell-attached proteins, extracellular proteases, and astrocyte-associated processes (e.g., [@bib205]; [@bib1]; [@bib287]; [@bib201]; [@bib250]). One thought is that these shared extracellular mechanisms serve in part to integrate phasic signaling processes across longer timeframes to broadly regulate the excitatory-inhibitory balance of the brain. Here we review some of the evidence that these extracellular processes play critical regulatory roles in both the circadian and sleep-wake systems.

3. Extracellular dynamics modulate circadian clock and sleep-wake systems {#s0030}
=========================================================================

3.1. Extracellular matrix (ECM) {#s0035}
-------------------------------

The extracellular landscape contains structural and enzymatic components that are as diverse in their composition as they are in their interactions. The neural ECM consists of molecules secreted by both neurons and astrocytes that become interlocked through covalent protein-protein and protein-carbohydrate interactions. Its composition varies regionally, developmentally, and activity-dependently. The ECM can serve as a structural scaffold, restrict diffusion of soluble factors, and has even been hypothesized to serve as a form of memory storage ([@bib265]). The importance of the ECM to neuronal signaling has led some researchers to designate it as the fourth "essential element" of a tetrapartite synapse, together with pre- and post-synaptic neurons and surrounding astrocytes ([@bib251]).

ECM molecules include chondroitin sulfate proteoglycans, heparin sulfate proteoglycans, collagen, elastin, laminin, fibronectin and hyaluronic acid. The ECM binds additional proteins, including growth factors, proteases, thrombospondins, tenascin C and R, reelin, vitronectin, plasminogen activator inhibitor-1 (PAI-1) and chemokines ([@bib119], [@bib242]). The ECM also binds to cell surface proteins/receptors, creating one avenue for modulating intracellular signaling ([@bib129]). Depending on its composition and interacting partners, the ECM can promote or deter cell growth and movement, and can enhance or inhibit cell-cell interactions ([@bib242]). We direct readers interested in more details concerning the composition and development of the ECM to several excellent reviews ([@bib284], [@bib242], [@bib63], [@bib148], [@bib197]). Although, to our knowledge, the ECM composition in the SCN and in sleep-wake regulating areas have not been investigated, evidence demonstrates that a variety of extracellular factors that interact with the ECM and/or are modulated by changes in the ECM, including neighboring astrocytes, regulate both systems. We explore these factors in more detail below.

3.2. Cell adhesion molecules (CAMs) {#s0040}
-----------------------------------

CAMs (including the immunoglobulin super family, integrins, neurexins, neuroligins, ephrins, Eph receptors, and cadherins) are a diverse group of cell-attached proteins that interact with each other and with the ECM. They can connect adjacent neurons as well as form neuron-astrocyte connections through interactions with the ECM and other cell attached proteins, often concurrently linking with intracellular scaffolding and cytoskeletal elements ([@bib261]). Through these interactions CAMs can create a syncytium that functionally integrates the activities of neighboring cells by uniting their intracellular and extracellular components. Here we focus primarily on the extracellular interactions of these molecules, while acknowledging that a comprehensive picture of their actions in these systems requires connecting the extracellular processes to those inside the cells.

### 3.2.1. Immunoglobulin super family: NCAMs and L1-CAMS {#s0045}

The immunoglobulin (Ig) super family of CAMs, which includes the neural cell adhesion molecules (NCAMs) and L1-CAMs, typically bind via their Ig domains to partners on neighboring cells rather than binding to the ECM ([@bib232], [@bib44]). In the intracellular compartment they modulate Ca^2+^ signaling, interact with cytoskeletal proteins, and alter the activity of multiple intracellular kinases ([@bib44], [@bib246]). A unique feature of NCAMs is that their interactions are sterically inhibited when they are expressed with a polysialic acid (PSA) carbohydrate chain covalently attached to their fifth Ig domain. This chain must be cleaved by an endopeptidase before transynaptic NCAM binding can occur ([@bib29], [@bib272]). PSA-NCAM is primarily expressed during neurodevelopment, while NCAM in the adult brain usually lacks PSA. However, PSA-NCAM is expressed in a few regions in the adult brain (e.g., hippocampus, amygdala, and supraoptic nucleus,) and its expression in these areas increases in response to glutamate stimulation ([@bib29], [@bib262], [@bib272]). The switch to PSA-NCAM is thought to allow long-term potentiation (LTP)- and learning-associated changes in synaptic structure ([@bib29], [@bib262], [@bib272], [@bib258]). Additionally, changes in NCAM expression have been linked to self-administration of drugs of abuse ([@bib232]), and changes in stress vulnerability in mice ([@bib258]). L1-CAM deficient mice do not exhibit deficits in LTP, but they show changes in hippocampal synaptic transmission, learning deficits, and increased stress vulnerability ([@bib258]). Similar to NCAM, changes in L1-CAM are seen with animal models of drug addiction ([@bib232]).

The SCN is one of the brain regions in which PSA-NCAM levels remain high in adulthood, and evidence indicates that PSA-NCAM is required for normal circadian function. Genetic deletion of NCAM or enzymatic removal of PSA with endoneuraminidase N (endo N) disrupts the period and stability of free-running locomotor activity in mice ([@bib244]), and inhibits light induced phase shifts of behavioral activity rhythms ([@bib94]). Endo N injections into the SCN *in vivo* reduce the number of light-induced c-Fos immunoreactive cells, particularly in the ventrolateral SCN ([@bib94]). Importantly, *in vitro* endo N administration prevents phase delays induced by either glutamate administration or electrical stimulation of the optic chiasm in rat SCN brain slices, indicating that PSA-NCAM\'s role is intrinsic to the SCN ([@bib223]). Endo N removal of PSA in the SCN also potentiates non-photic circadian phase resetting ([@bib74]). These studies demonstrate the importance of PSA-NCAM for normal circadian clock entrainment.

PSA-NCAM mediates synaptic cell-cell interactions in other brain regions, and its localization pattern in the SCN suggests it may play a similar role there. In the adult mouse SCN, PSA-NCAM is localized on neuronal somas in the central SCN and adjacent to synaptic junctions, but very little is seen in the ventral SCN ([@bib244]). PSA often is associated with cells expressing light-induced c-Fos, which are generally cells that receive retinal input ([@bib95]). In SCN astrocytes, PSA-NCAM is predominately located along fine processes between opposing neuronal somas and associated with synaptic junctions and small blood vessels, but not on larger processes or cell bodies ([@bib244]).

There are striking circadian changes in PSA-NCAM expression in the SCN. In hamster SCN, PSA expression is rhythmic in both light-dark (LD) and constant dark (DD) conditions, with higher levels during the day than at night ([@bib95]). Similar rhythms are found in rat SCN maintained *in vitro* ([@bib223]). The *in vivo* PSA rhythms are slightly blunted in DD conditions, suggesting regulation by both the circadian clock and photic input ([@bib95]). Consistent with this conclusion, PSA expression in the SCN is induced *in vivo* by light stimulation at CT19, and *in vitro* by glutamate treatment ([@bib95], [@bib223]). The exact nature of PSA's role in phase shifting is still not known, but the induction of PSA by light together with the effects seen in response to PSA removal suggests a role in photic signaling ([@bib95]). Interestingly, while glutamate does not generate phase shifts during the daytime, it still induces PSA expression at this time, indicating that while PSA induction may be involved in the phase shifting process, PSA induction by itself is not sufficient to generate phase shifts ([@bib223]).

Coordinating and synchronizing cells within the SCN could involve NCAM acting through both PSA-dependent and --independent mechanisms. Initial assessments of NCAM in the SCN utilized a transgenic NCAM knockout that completely lacks the *Ncam* gene ([@bib244]). However, *Ncam* encodes three NCAM isoforms (180,140, and 120 kDa) that have distinct structures and functions. NCAM 180 is the isoform that is glycosylated with PSA; NCAM 180 and NCAM 140 are transmembrane proteins with intracellular regions; and NCAM 120 is membrane-attached with no intracellular region. A comparison of the entrainment and phase-resetting phenotypes of different NCAM isoform knockouts supports the hypothesis that NCAM, but not PSA, is needed for synchronization to LD cycles, while PSA and its NCAM carrier are important for free-running periods in DD ([@bib245]). However, the molecular mechanisms through which PSA-NCAM gates phase shifting are still unclear. One possibility is that PSA interacts with secreted factors such as brain-derived neurotrophic factor (BDNF). To this end, it has been shown that endo N removal of PSA from NCAM in the SCN abolishes the sensitizing effect of BDNF on mouse photic phase resetting ([@bib93]). Interactions with L1--CAM may also be important for PSA-NCAM\'s role in the SCN. L1-CAM protein is expressed at high levels in the SCN, and appears to be associated with retinal inputs ([@bib292]). Continuous infusion of anti-L1-CAM antibody into the 3^rd^ ventricle disrupts circadian rhythms during the infusion period and results in a phase shift in the free running rhythm of locomotor activity for several days after infusion ([@bib291]). In summary, although the detailed mechanisms remain unclear, PSA-NCAM appears critical for photic phase resetting in the SCN.

Research suggests that PSA-NCAM is also important in the sleep system. For example, PSA-NCAM is found surrounding wake-promoting neurons in the adult hypothalamus and brainstem, and to a lesser extent around neurons in sleep-promoting brain regions like the VLPO and the ventrolateral periaqueductal gray ([@bib19]). PSA is also expressed at high levels in the nucleus of the solitary tract (NST), a brainstem area associated with sympathetic nerve activity and arousal state ([@bib21]). These authors found that endo N alters astrocyte morphology and neuronal activity in the NST. Regarding sleep regulation more directly, another study found that six hours of sleep deprivation increases PSA-NCAM immunoreactivity in the median eminence of the hypothalamus, while removing PSA with endo N decreases REMS during the latter part of the sleep period, decreases the number of REMS episodes, and shortens the mean duration of REMS in rats ([@bib19]). These data suggest that PSA-NCAM-dependent synaptic restructuring is necessary for REMS production. As with the circadian system, much more work is needed to understand the extent and mechanisms of its involvement in sleep regulation.

### 3.2.2. Neurexins and Neuroligins {#s0050}

Another set of CAMs includes the neurexins, which are located on presynaptic neurons, and their neuroligin binding partners, which are located postsynaptically or on astrocytes ([@bib228], [@bib232]). Although they have not been investigated extensively in the adult brain, evidence suggests that changes in neurexin expression accompany changes in synaptic signaling that occur after repeated cocaine exposure ([@bib128]). Neuroligins can signal in both anterograde and retrograde directions to alter synaptic signaling properties ([@bib83], [@bib153], [@bib122]). Importantly, neuroligin-neurexin interactions are modulated by extracellular proteases ([@bib251]).

Neurexins and neuroligins may play a role in mediating the diurnal variations in neuronal activity in the SCN. Cell autonomous, diurnal rhythms have been found in the expression and splicing of neurexin genes in the SCN of mice ([@bib243]). Neurexin genes (*Nrx1/2/3*) encode two families (α and β) each with multiple splice variants ([@bib228]). Diurnal rhythms are found in the transcription of some but not all variants ([@bib243]). Consistent with these data, a separate report indicates that expression of the neurexin binding partner, *Nlg1*, is higher in the day than the night in mouse forebrain. Moreover, several E-boxes were found upstream of *Nlg1*, and the binding of BMAL1 and CLOCK to one E-box varies with the time of day ([@bib67]).

Since neurexins can influence the excitatory/inhibitory synaptic balance, their expression in relation to post-synaptic scaffolding proteins (PSD-95 and gephryn) was assessed in the SCN. Protein levels of PSD-95, gephyrin, and neurexin-2α exhibit diurnal variations in the mouse SCN *in vivo*. Gephryin levels are elevated in the dark period and minimal in the day, while PSD-95 levels are high during the day and low at night ([@bib243]). Similar rhythms in these mRNA transcripts and proteins are seen in immortalized rat SCN2.2 cells ([@bib243]). Importantly, siRNA mediated suppression of neurexin transcripts in SCN2.2 cells affects the levels of gephyrin and PSD-95, supporting a role for neurexin transcripts in maintaining circadian rhythms in these synaptic scaffold proteins ([@bib243]). These data raise the exciting possibility that circadian rhythms in neurexin expression influence the excitatory-inhibitory synaptic balance in the SCN and/or daily rhythms in synaptic remodeling.

Neuroligins also influence sleep processes. Sleep deprivation decreases expression of *Nlg1* in mouse forebrain, with results indicating that increased sleep pressure decreases the expression of *Nlg1* containing an insert in splice site B ([@bib67]). These changes are correlated with decreases in synaptic NLG1 levels in the anterior forebrain of mice. Additionally, *Nlg1* knockout mice have decreased wakefulness and increased SWS. Sleep deprivation also decreases binding of transcription factors to the *Nlg1* E-box (mentioned above), suggesting a possible connection between circadian and sleep homeostatic modulation of *Nlg1* expression ([@bib67]).

A second study found similar changes in sleep-wake regulation in *Nlg1* knockout mice, with evidence for enhanced neuronal synchrony in these mice during sleep ([@bib164]). Interestingly, using transcriptomics, they found that sleep deprivation induces similar changes in gene expression in both *Nlg1* knockout and wildtype mice, suggesting the synaptic changes in *Nlg1* expression may be downstream of the molecular pathways driving the transcriptional response to sleep ([@bib164]). They also found differentially methylated and hydroxymethylated genomic regions following sleep deprivation that implicate molecular pathways involved in neurotransmission, cellular assembly, and metabolism ([@bib164]). In particular, members of the *Nrx*-*Nlg* family were differentially hydroxymethylated following sleep deprivation ([@bib164]).

Interestingly, transgenic mice expressing a form of *Nlg3* with a missense mutation exhibit altered EEG spectral profiles even though they exhibit a normal duration and distribution of sleep-wake states ([@bib154]). These changes are different from those seen in *Nlg1* knockout mice, suggesting distinct roles for different neuroligin family members ([@bib154]). The idea of differential neuroligin involvement in sleep regulation is further supported by data showing that immunohistochemical expression of neuroligin 2 increases in wakefulness-promoting orexin neurons in the LH of mice subjected to 6 hours of sleep deprivation ([@bib165]). The authors also found that in these same orexin neurons the expression of α1 subunit-containing GABA~A~ receptors increases after 6 hours of sleep deprivation ([@bib165]). Because GABA release by VLPO neurons promotes sleep in part by inhibiting orexin neurons ([@bib137]), further investigation of the mechanism behind neuroligin 2 regulation of the α1-GABA ~A~-receptors could clarify the role(s) of cellular adhesion molecules in sleep.

The involvement of neuroligins in sleep is further corroborated by research in *Drosophila*, in which null mutant *dNlg4* flies exhibit abnormal sleep behavior, sleeping significantly less each night with longer sleep onset latency than wildtype flies ([@bib149]). They also exhibit more sleep episodes and shorter sleep-bout duration, suggesting disrupted sleep consolidation ([@bib149]). *DNlg4* is expressed in large ventrolateral clock neurons, and whole-cell current-clamp recordings of these neurons indicate that d*Nlg4* flies have impaired GABA transmission. Collectively, their results demonstrate that *dNlg4* regulates sleep in *Drosophila* by modulating inhibitory synapse function ([@bib149]).

Neurexins have not been studied as extensively with respect to sleep regulation. However, in *Drosophila*, *dNrx1* gene inactivation decreases the total amount of daytime sleep ([@bib141]). Moreover, deletion of neurexin using two null mutant *Drosophila* strains (*nrx*^*273*^ and *nrx*^*Δ83*^) reduces nighttime sleep, decreases sleep episode length, and increases the number of sleep episodes ([@bib264]). Data demonstrating that a trans-heterozygote strain with a partial reduction in neurexin expression exhibits a corresponding decrease in sleep suggests that the amount of sleep loss is correlated with the amount of neurexin reduction. Mechanistically, the effect on sleep in response to neurexin knockout or reduction appears to be due to decreased Ca^2+^ signaling ([@bib264]).

In summary, there is growing evidence supporting neurexin/neuroligin involvement in both the circadian and sleep-wake systems. Moreover, the *Drosophila* results along with data showing CLOCK/BMAL regulation of sleep-associated neuroligin expression suggests an enticing regulatory link between the two systems involving CAMs. Nevertheless, there are critical gaps in our understanding of the mechanisms through which they participate in circadian and sleep-wake processes. In particular, how changes in their expression and/or interactions within the extracellular space translate into changes in intracellular signaling has yet to be elucidated. With respect to the sleep-wake system in particular, more information on regionally specific roles of neurexin and neuroligin is also needed.

### 3.2.3. Shank3 {#s0055}

Shank3 is a postsynaptic scaffolding protein that interacts with neuroligins and glutamate receptors, and can regulate synaptic plasticity in part through changing the structural organization of dendritic spines ([@bib113], [@bib198]). Thus, while not technically a CAM, evidence supporting its involvement in circadian rhythms and sleep-wake regulation makes it worth mentioning in this context. Time-of-day dependent differences in Shank3α expression are seen in the hippocampus and striatum of mice housed in LD conditions that correlate with rhythms in serum melatonin levels ([@bib235]). Eight weeks after reversal of the LD cycle the rhythms of Shank3 in the hippocampus are reversed, while the rhythms in the striatum remain unchanged ([@bib235]). The authors interpreted this to mean that Shank3 expression is modulated by both circadian and non-circadian mechanisms. They also found that physical activity increases Shank3 in the thalamus and cortex, while it decreases Shank3 in the striatum ([@bib235]). While Shank3 levels have not been assessed in the SCN or in DD conditions, the diurnal variations across multiple brain regions combined with the evidence pointing to dynamic synaptic structure in the SCN (discussed below) suggest that an investigation of Shank3 proteins in the SCN is warranted.

Shank3 may also participate in sleep regulation. Genomic analysis of patients with clinical conditions that include experiencing epileptic seizures during SWS (e.g., Landau-Kleffner syndrome) revealed that a number of genes associated with cellular adhesion molecules, including *Shank3*, contain variations in copy number ([@bib147]). Although the pathology of these syndromes is likely multifactorial, the rhythms in Shank3 expression mentioned above raise the possibility that it may be important for sleep state transitions.

### 3.2.4. Eph-ephrins {#s0060}

Another group of CAMs that has been implicated in both the circadian and sleep-wake systems includes the Eph receptors and their ephrin ligands. Eph receptors, which are tyrosine kinase receptors, are categorized as A-type or B-type, with A-type primarily binding ephrinA\'s and B-type binding ephrinB\'s ([@bib59]). Eph receptors and their ligands are both membrane-bound, can connect neighboring neurons and astrocytes, and can signal in both anterograde and retrograde directions ([@bib207], [@bib261], [@bib59]). Eph-ephrin signaling is important during neurodevelopment, where it participates in cell-cell attraction and repulsion, as well as modulating dendritic spine morphology and synapse formation ([@bib59]). In the adult brain Ephs and their ligands are important for modulating memory formation and synaptic plasticity events in the hippocampus and other limbic areas ([@bib59], [@bib280]).

Eph-ephrin interactions have not been studied extensively in the SCN, but there are a couple of studies that point to their involvement in circadian clock mechanisms. The EphA4 receptor is expressed in the SCN and its expression is decreased in *Clock* mutant mice ([@bib82]). Additionally, the number of PER1 immunoreactive cells is reduced in the SCN of EphA4^-/-^ mice when compared to wildtype mice ([@bib130]). EphA4^-/-^ mice exhibit reduced wheel-running activity, longer endogenous periods under DD, and shorter periods under constant light compared to their wildtype counterparts ([@bib130]). EphA4^-/-^ mice also exhibit smaller phase delays in response to light pulses during the early subjective night, and a corresponding reduction in light-induced c-FOS expression ([@bib130]). Thus, EphA4 is required for the normal maintenance and entrainment of circadian rhythms, but the molecular mechanisms through which EphA4 acts are not clear. In the adult hippocampus, EphA4 promotes the retraction of dendritic spines and down regulation of AMPARs ([@bib190]). It is possible that EphA4 plays a similar role in the SCN, where daily rearrangements in astrocytic processes have been extensively characterized (see below).

Eph-ephrin interactions are also implicated in sleep regulation. For example, EphA4 knockout mice exhibit reduced levels of REMS ([@bib82]). They also have reduced SWS, both at baseline and after 6 hr sleep deprivation, with data suggesting a role for Eph4a in shaping cortical oscillations but not necessarily in the response to elevated sleep pressure ([@bib82]). Conversely, two microarray studies found decreases in the expression of *Ephrin B3* in the forebrain \[([@bib181]) discussed in [@bib197]\] and cortex ([@bib158]) of wildtype mice undergoing sleep deprivation. Together with the previously reviewed data on NCAM and neurexin/neuroligin involvement in the sleep-wake system, the molecular response to sleep deprivation may include changing the mixture of CAMs and other extracellular-interacting receptors in order to alter synaptic signaling parameters. Further, these extracellular molecules appear to be necessary for maintaining normal sleep architecture. Future research examining the differential expression and regulation of these molecules and elucidating their interactions with intracellular signaling processes will clarify their role in maintaining both circadian and sleep homeostasis.

### 3.2.5. Integrins {#s0065}

Integrins are CAM heterodimers composed of α and β subunits, where the α subunit confers ligand specificity and the β subunit interacts with intracellular factors to initiate signaling cascades. Activation of integrins can be "inside-out", where an initial intracellular ligand binds to the β subunit thereby altering interactions of the α subunit with its extracellular ligands, or "outside-in", where the initial stimulus is an extracellular ligand binding to the α subunit, which in turn affects β subunit intracellular actions ([@bib208]). Integrins are important for synaptic plasticity. During hippocampal LTP, β1- and β3-integrins participate in altering dendritic morphology, glycine receptor expression, and glutamate receptor signaling ([@bib208]). Likewise, cocaine addiction-associated synaptic plasticity the nucleus accumbens involves β3-integrin-induced changes in AMPAR and BDNF levels ([@bib297]).

The involvement of integrins in the SCN circadian clock has, to our knowledge, not been investigated. However, there is evidence for integrins participating in sleep regulation. For example, in an investigation that screened human saliva for markers of sleep deprivation, individuals who experienced 30 hours of sleep loss have higher Integrin αM levels. They also found that sleep deprivation increases the expression of a homologous protein, Integrin α5, in *Drosophila* ([@bib263]). A separate study found that sleep deprived mice exhibit decreases in *Integrin α4* and increases in *Integrin* α*10* in the forebrain \[([@bib181]), discussed in [@bib197]\]. Finally, a microarray study found sleep-induced changes in mRNA expression for several integrins in the cortex ([@bib157]). Although these data provide no mechanistic details, they support functional roles for integrins in sleep. Given the known parallels between synaptic plasticity mechanisms and those involved in the circadian and sleep-wake systems, we believe that additional research exploring integrin actions within both systems would be informative.

In summary, there is broad evidence for CAMs participating in both the circadian and sleep-wake systems ([Fig. 1](#f0005){ref-type="fig"}, [Table 1](#t0005){ref-type="table"}). The degree of support varies between the two systems and on the specific type of CAM. In many cases the data are just correlational, while in some cases the evidence includes more functional detail. Nevertheless, one could postulate that through their ability to structurally connect neurons and astrocytes to each other and to the ECM, CAMs may dynamically modulate cell coupling within both the circadian clock and sleep-wake systems in ways that broadly shift the neuronal excitatory/inhibitory signaling balance. However, much more research is needed to clarify the mechanisms involved, and how much they are the same or different between the two systems.Fig. 1Cell adhesion molecules implicated in SCN circadian system (A) and sleep-wake system (B) modulation. For the sleep-wake system, note that the figure collates data from a variety of brain regions. The strength of the data in both systems varies, from simple mRNA or protein expression through extensive functional evidence. The figure does not attempt to represent all of the cell adhesion molecules, transmitters, or interactions that are known or theorized to participate in each system, but rather aims to illustrate the potential commonalities and differences between the systems.Fig. 1Table 1Summary of evidence supporting involvement of extracellular interacting proteins and molecules in the SCN circadian system and sleep-wake system.Table 1**ProteinGeneral functionCircadian Rhythm Effects in SCNSleep Effects Across Brain RegionsCitationsCAMs & related**EphA4Cell adhesion moleculeDisrupted circadian function in EphA4^-/-^ mice; necessary for maintenance and entrainment of circadian clocks, expressed in SCN and expression decreases in *Clock* mutant miceEphA4-/- mice display reduced REMS, and reduced NREMS.[@bib130]; [@bib82]*Ephrin B3*Cell adhesion moleculeUnknownSleep deprivation decreases expression of *Ephrin B3* in forebrain and cortex.[@bib181]; [@bib157]; [@bib197]IntegrinsCell adhesion moleculeUnknownIncreased levels of αM integrin in human saliva after 30 h sleep loss; sleep deprivation decreases *Integrin α4* and increases *Integrin α10;* sleep deprivation in *Drosophila* increases α5-integrin expression; sleep induces changes in integrin mRNA expression in cortex[@bib263]; [@bib197]; [@bib157]; [@bib181]L1-CAMCell adhesion moleculeInfusion disrupts circadian phase shifts and SCN architectureunknown[@bib291]; [@bib292](PSA)-NCAMCell adhesion moleculeInduced by light and involved in circadian clock entrainment; removal of PSA disrupts circadian rhythms; protein expression high during day, low at night; localized to neuronal somas and astrocytic fine processes in SCNExpressed in hypothalamus, brainstem, VLPO, ventrolateral periaqueductal grey; increased immunoreactivity in median eminence after sleep deprivation; removal of PSA in brain decreases REMS, decreases REMS episodes and shortens mean duration of REMS[@bib244]; [@bib94]; [@bib223]; [@bib74]; [@bib95]; [@bib245]; [@bib93]; [@bib19]; [@bib21]NeurexinsPresynaptic CAMCircadian rhythm in neurexin 2α gene transcription*dNrx1* gene inactivation and neurexin deletion decreases sleep in *Drosophila*[@bib243]; [@bib264]; [@bib141]NeuroliginsPostsynaptic CAMBinding of BMAL1 and CLOCK exhibits diurnal rhythm in forebrainSleep deprivation influences expression levels of *Nlg1*and *Nlg2; Nlg1* knockout mice have decreased wakefullness/increased SWS; Missense mutation in *Nlg3* alters EEG spectral profiles; *dNlg4* regulates sleep in *Drosophila*[@bib165]; [@bib67]; [@bib164]; [@bib154]; [@bib149]Shank3Postsynaptic scaffolding proteinTime-of-day dependent rhythms in expressionPatients with epileptic seizures during SWS have variations in copy number of *Shank3* gene[@bib235]; [@bib147]        **Extracellular protease-related**BDNFGrowth factorHeterozygous knockout mice have reduced photic phase shifts; needed for glutamate-induced phase shifting; allows photic phase shifts during the day; mRNA and protein are high at night, low during the dayCortical mRNA levels increase after sleep deprivation; injections of BDNF increase SWS in mice; in PPT and subcoeruleus nucleus, protein expression increases after REMS disruption[@bib188]; [@bib151]; [@bib150]; [@bib173]; [@bib260]; [@bib51]; [@bib10]; [@bib73]; [@bib188]LRP-1Membrane bound receptorExpressed in the SCN; required for glutamate-induced phase shifts in vitro; heavy chain portion expression is high at night, low in daySleep deprivation decreases soluble LRP-1 levels in blood plasma; LRP-1 mRNA increases in cortex during sleep[@bib48]; [@bib279]; [@bib157]MMP-2/9ProteasesExpressed in the SCN; inhibiting induces phase shifts; protein expression not rhythmic; decreased MMP9 activity at ZT23Cortical/hippocampal mRNA levels decrease after sleep deprivation[@bib105]; [@bib260]NeuroserpinInhibits tPA/uPAProtein expression is high in day, low at night; neuroserpin antibody allows glutamate phase shifts in the day in vitroUnknownProsser & Conner, unpublished dataPAI-1Inhibitor of tPAExpressed in the SCN; blocks glutamate induced phase shifts in vitroIncreased expression in blood of female shift workers with poor sleep quality[@bib188]; [@bib192]PlasminCleave BDNFExpressed in the SCN; inhibiting blocks glutamate-induced phase shiftUnknown[@bib188]tPACleave plasminogenInvolved in glutamate-induced phase shifting; influences food anticipatory behavior; rhythmic protein expression in vitro with higher levels at nightIn mice, cortical mRNA levels increase after sleep deprivation[@bib260]; [@bib188]; [@bib47]; [@bib132]TrkBMembrane bound receptor of BDNFImportant for glutamate-induced phase resettingInhibiting PPT reduces REM sleep, suggesting TrkB activation is necessary for increase in REMS homeostatic drive; truncated TrkB, lacking kinase domain, increases total REMS and decreases latency to REMS[@bib188]; [@bib10]; [@bib150]; [@bib173]; [@bib278]uPACleave plasminogenSupports phase shift in absence of tPA; no circadian rhythm detected in vitroUnknown[@bib47]VitronectinECM MoleculeRegulation of tPA by PAI-1 requires VNUnknown[@bib188]          **Gliotransmitters**AdenosineNucleosideAdenosine acting on A~1~ receptors can phase-shift the SCN clock and block photic phase shifts; at least some actions involve inhibiting glutamate releaseInhibits wake-promoting neurons via A~2a~ receptors; lack of adenosine increases SWS time and enhances SWS after sleep deprivation; astrocyte-derived adenosine modulates sleep; glucose stimulates astrocytic release of adenosine in VLPO[@bib112]; [@bib285]; [@bib5]; [@bib277]; [@bib69]; [@bib249]; [@bib104]; [@bib103]; [@bib20]; [@bib238]ATPNucleotideGenes involved in ATP regulation exhibit circadian rhythms; circadian variation in production and accumulation of extracellular ATP in SCN2.2 cells and rat in vivoMice lacking pannexin-1 channel have inverted wake/SWS ratio and increased activity in light and dark. ATP agonists increase SWS in mice. ATP PX27 receptor expression varies with sleep state. ATP increases astrocytic release of IL1β and TNFα.[@bib170]; [@bib285]; [@bib131]; [@bib136]; [@bib134]; [@bib120].InterleukinsCytokinesIL1β and IL-6 exhibit circadian patterns of expression in human plasma. Decreased *Per* and *Cry* expression in liver, fibroblasts and neuronal cell cultures and decrease behavioral activity in mice. Peak mRNA expression during light phase. Hippocampal microglia exhibit diurnal expression of IL1β.IL1β protein and mRNA levels increase during wakefulness and decrease during sleep.Low doses of IL1β increase SWS while high doses suppress SWS and REMS. Mice lacking IL1β receptors have less SWS and REMS during active period. Sleep regulatory regions in the brain (cortex, brainstem and hypothalamus) contain glia expressing IL1β. Selective expression of IL1β receptor to neurons or astrocytes prevents IL1β-induced increases in sleep. Astrocytic IL1β receptors required for proper REM, NREM sleep, and production of IL-6 protein in the hypothalamus. IL-6 increases in mice that experienced sleep fragmentation.[@bib12]; [@bib274], [@bib273]; [@bib34]; [@bib259]; [@bib267]; [@bib80]; [@bib80]; [@bib114]; [@bib56]. [@bib116]; [@bib115]. [@bib134].TNFαCytokinePlasma expression of TNFα exhibits circadian rhythms; regulates LPS-induced phase shifts of locomotor activity rhythms in mice; decreases *Per* and *Cry* expression in liver, fibroblasts and neuronal cell cultures and behavioral activity in mice. Peak mRNA expression during light phase. TNFα decreases expression of *Dpb* mRNA in SCN tissue. TNFα shifts PER2 rhythms in SCN astrocyte cultures. Hippocampal microglia exhibit diurnal expression of TNFα.Wakefulness increases mRNA and protein expression of TNFα while inhibiting its activity can decrease sleep. Increases in TNFα accompany sleep fragmentation and decreased sleep quality in mice and humans. TNFα is expressed by glia in sleep regulatory regions of the brain (cortex, brainstem, and hypothalamus). TNFα receptor knockouts exhibit decreased SWS and REMS late in their active period and entire sleep period. Increases and fragments NREM sleep, inhibits REM sleep. TNFα enhances sleep like states (i.e. burstiness, synchronization and slow wave power) of cultured cortical astrocytes.[@bib24]; [@bib26]; [@bib34]; [@bib32]; [@bib86]; [@bib267]; [@bib64]; [@bib80]; [@bib80]; [@bib114]; [@bib121]. [@bib134].Nitric oxideSecreted gaseous moleculeFound in SCN astrocytes; modulates photic transduction; hemoglobin scavenging of NO blocks some but not all circadian effectsWakefullness and sleep deprivation increase NO production by NOS; *Nos3* expression in cerebral cortex increases during sleep; *nNOS*^-/-^ mice have decreased SWS; in sleep deprived mice nNOS inhibition in basal forebrain decreases REM sleep recovery while iNOS inhibition prevents SWS recovery[@bib60]; [@bib97]; [@bib218]; [@bib8]; [@bib31]; [@bib28]; [@bib157]; [@bib185]; [@bib125]

3.3. Extracellular proteases {#s0070}
----------------------------

The ECM is a dynamic structure constantly being remodeled in response to extracellular proteases secreted by the surrounding cells. Extracellular proteases in the brain include thrombin, neurotrypsin, neuropsin, plasminogen, tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), and matrix metalloproteinases (MMPs). Several of these proteases have been implicated in both circadian clock and sleep-wake regulation. Although we focus primarily on their actions within the extracellular space, we provide information on their effects on intracellular signaling associated with the circadian and sleep-wake systems when it is available.

### 3.3.1. tPA and uPA {#s0075}

tPA and uPA are extracellular serine proteases produced and secreted by neurons and astrocytes in many regions of the brain, including the cortex, limbic system, hypothalamus, and cerebellum ([@bib124], [@bib221], [@bib163], [@bib145], [@bib167]). tPA and uPA share their plasminogen activating function (cleaving plasminogen to form active plasmin), upstream inhibitors (including PAI-1 and neuroserpin), downstream targets (including ECM molecules, MMPs, CAMs, and plasminogen) ([@bib2]), and some membrane-localized receptors, including low density lipoprotein receptor-related protein 1 (LRP-1) and annexin II ([@bib6], [@bib38]). However, the two proteases also diverge in various ways, including their mechanisms of activation and cell signaling actions.

tPA's well established role as a neuromodulator is elegantly described in a recent review ([@bib167]). Some tPA-induced effects on hippocampal learning, LTP, and LTP-associated synapse formation involve proteolytic formation of plasmin from plasminogen, followed by proteolytic activation of proBDNF to form mature BDNF (mBDNF) ([@bib79], [@bib204], [@bib203]). tPA has also been shown to modulate amygdala- and hippocampus-based synaptic plasticity through both direct and indirect interactions with NMDAR subunits ([@bib196], [@bib213], [@bib214], [@bib212], [@bib296], [@bib199], [@bib195], [@bib196], [@bib213], [@bib214]). tPA can bind to cell-surface receptors, including LRP-1, annexin II, and epidermal growth factor receptor ([@bib38], [@bib298], [@bib175]), which can stimulate receptor-mediated signaling, restrict its sphere of activity, and modify its proteolytic activity ([@bib175], [@bib38]).

uPA also participates in synaptic remodeling, with the majority of uPA research in this area focused on its role in neural repair following stroke or spinal cord damage ([@bib171], [@bib241], [@bib288]). Many of uPA's actions require binding to its uPA receptor (uPAR). Ligand-bound uPAR interacts with other cell-surface proteins, including LRP-1, integrins, and receptor tyrosine kinases. In most cases, these interactions result in internalization of the receptor-protein-ligand complex ([@bib175], [@bib271], [@bib159]).

Many uPA and tPA inhibitors, including PAI-1, PAI-2, neuroserpin, and proteinase nexin 1, are expressed in the brain ([@bib88], [@bib268]). Of these, PAI-1 is unique in having to bind vitronectin to remain active ([@bib54]). Because vitronectin typically binds to the ECM, this can serve to restrict the location and activity of PAI-1 ([@bib179], [@bib219]). Neuroserpin, thought to be expressed solely within the central nervous system ([@bib107], [@bib180]), can also modulate cell adhesion through a tPA-independent mechanism that may involve cleavage of the CAM, N-cadherin ([@bib144]).

One of the first indications that extracellular proteases influence the SCN circadian clock was data showing that the plasminogen activating cascade regulates SCN clock phase resetting. Proteins within this enzymatic cascade, including tPA, uPA, PAI-1, vitronectin, plasminogen, and plasmin are all expressed in the SCN ([@bib188], [@bib47]). tPA expression in the SCN is rhythmic, with high levels at night and low levels during the day ([@bib47]). Inhibiting tPA or plasmin (with PAI-1 or α~2~-antiplasmin, respectively) prevents glutamate-induced phase delays and phase advances of the SCN circadian clock *in vitro* ([@bib188]).

Exactly how tPA modulates photic phase resetting is not clear, but one strong possibility is that it enhances BDNF signaling. As mentioned earlier, plasmin can cleave proBDNF to generate mBDNF. mBDNF activation of its receptor, TrkB, may contribute to restricting photic phase shifting to the night. Similar to tPA, BDNF levels are higher in the SCN at night and lower during the day ([@bib151]). Moreover, tPA^-/-^ mice have less mBDNF in the SCN than wildtype mice ([@bib47], [@bib132]). Blocking TrkB receptors inhibits light- and glutamate-induced phase shifts ([@bib150], [@bib173]), and light-induced phase shifts are attenuated in BDNF heterozygous mice ([@bib150]). Also, administration of exogenous BDNF during the subjective day allows light and glutamate-induced shifts to occur when they normally would not ([@bib150], [@bib173], [@bib188]). Importantly, inhibition of glutamate-induced phase shifts by blocking tPA activity is reversed by co-administration of plasmin or mBDNF, but not plasminogen or proBDNF ([@bib188]). Together, these data support a scenario where tPA acts upstream of mBDNF as part of a gating mechanism that restricts photic/glutamate phase shifts to the night: at night, when tPA levels are high, tPA cleaves plasminogen into plasmin, which then cleaves proBDNF to mBDNF. TrkB receptor activation by mBDNF enhances the ability of glutamate signals to induce phase shifts.

[@bib188] further demonstrated that endogenous regulation of tPA activity in the SCN by PAI-1 requires vitronectin, since PAI-1 does not block phase shifts in brain slices prepared from vitronectin knockout mice ([@bib188]). Interestingly, tPA activity in the SCN may also be regulated by neuroserpin. Preliminary data indicates that neuroserpin is expressed at higher levels in the day than the night in the SCN, and co-application of a neuroserpin antibody (to inhibit neuroserpin activity) with glutamate to SCN brain slices during the daytime induces a 3 h phase advance that is not seen with glutamate application alone (Prosser and Conner, unpublished data). Together, these data support tPA regulation of circadian clock phase control. However, more research on tPA's downstream actions and upstream regulators is needed to fully elucidate the mechanisms through which the plasminogen pathway influences circadian clock function and how the circadian clock in turn feeds back on these processes.

Given the data presented above, it is somewhat surprising that tPA^-/-^ mice entrain normally to LD cycles and exhibit minimal changes in sensitivity to light-induced phase-shifts *in vivo* or glutamate-induced phase shifts *in vitro*. The only discernable deficiency in light entrainment is that tPA knockout mice re-entrain to either an inverted light cycle or to a 6 h advance in the light cycle more slowly than wildtype litter mates ([@bib47], [@bib132]). It is also interesting to note that tPA modulates food anticipatory behavior driven by a food-entrainable circadian oscillator that functions independently of the SCN clock ([@bib132]). This study found that tPA knockout mice have reduced wheel running activity compared to wildtype mice and altered behavioral activity patterns in response to fasting and temporally restricted food availability. The mechanisms underlying these effects remain unclear, but tPA's involvement in food-entrained circadian behavior together with the effects of tPA seen *in vitro* underscores the diverse roles extracellular proteases can play in circadian oscillators.

While exploring these findings, it was determined that uPA also regulates glutamate-induced phase shifts in the SCN. The initial evidence that uPA functions in the SCN was the finding that PAI-1, which is only known to inhibit tPA and uPA, continues to block glutamate-induced phase delays in brain slices from tPA^-/-^ mice ([@bib47]). Further, selective inhibition of uPA prevents glutamate induced phase shifts in tPA^-/-^ but not wildtype SCN tissue, suggesting that in tPA^-/-^ mice, uPA can compensate for the lack of tPA. Thus, it appears that either plasminogen activator is sufficient but neither is necessary for phase shifting to occur ([@bib47]).

Although the data suggest that tPA and uPA function in parallel to support glutamate-induced phase shifts, their regulation and mechanisms of action appear to be distinct. First, tPA and uPA differ in both their expression and activity patterns in the SCN *in vitro*. tPA expression exhibits a circadian rhythm, with higher levels at night than day, while uPA expression is not rhythmic. Additionally, using casein-plasminogen zymography as a preliminary measure of proteolytic activity in the SCN, no circadian rhythm is seen in either tPA or uPA activity ([@bib47]). Finally, unlike with tPA ([@bib47], [@bib132]), inhibiting uPA does not change mBDNF levels in the SCN, suggesting that uPA in the SCN acts independently of mBDNF generation ([@bib47]). Taken together, these data demonstrate that tPA and uPA play functionally redundant roles regarding glutamate-induced phase resetting, but they are modulated separately and act through divergent pathways that need further investigation.

### 3.3.2. Matrix metalloproteinases (MMPs) {#s0080}

MMPs are a well-studied family of ECM-targeting proteases that can be categorized based on their substrates, e.g., whether they degrade collagen (collagenases; MMP-1, -8, and -13), or gelatin (gelatinases, MMP-2 and -9), or by their localization, e.g., whether they are membrane-bound (MT-MMPs) or soluble. There are also MMP-related proteases, including the membrane-bound a disintegrin and metalloproteinases (ADAMs) and secreted ADAMTs (ADAMs with thrombospondin motifs) ([@bib251]). MMPs can be activated by other MMPs and by serine proteases, and are inhibited by tissue inhibitor of metalloproteases (TIMPs) ([@bib162]; [@bib293], [@bib234], [@bib280]). Substantial attention has been given to the actions of MMP-9 in the brain. Both increasing and decreasing MMP-9 expression can disrupt hippocampal LTP ([@bib280]). Increases in MMP-9 are seen in the nucleus accumbens and amygdala during withdrawal from drugs of abuse, and MMP-9-induced changes in dendritic structure in these regions enhance the propensity for relapse ([@bib254]). MMP-9 has been shown to modulate NMDAR membrane localization ([@bib11]), possibly through cleavage of cell-surface β-dystroglycan, Eph-ephrin proteins, or neuroligin 1 ([@bib172], [@bib87], [@bib215]), which in turn can affect intracellular scaffolding proteins such as PSD-95. MMP-9 can also cleave proBDNF to generate mBDNF, allowing it to activate its TrkB receptor and enhance NMDAR signaling ([@bib280]). MMP-9 enhancement of LTP could also involve cleaving cell-surface integrins and thereby disrupting cell attachments ([@bib280]).

MMPs also influence SCN timekeeping. Inhibiting MMP-2 and 9 *in vitro* in the SCN induces phase shifts that are time-of-day dependent: MMP-2/9 inhibition induces phase advances when treatments are applied during mid-subjective day and early subjective night, but not when applied during late night ([@bib105]). These phase shifts appear to involve distinct signaling mechanisms. Although both daytime and nighttime phase-shifts induced by MMP-2/9 inhibition require activation of NMDARs, activation of plasmin and the TrkB receptor are required for daytime phase advances but not early night phase delays. Neither MMP-2 nor MMP-9 exhibit circadian rhythms in protein expression in the SCN. However, MMP-9 proteolytic activity is lowest during late night, corresponding with the time when MMP-2/9 inhibition does not phase-shift the clock. Additional research into whether MMP-2 and MMP-9 modulate the circadian clock through other known substrates, including glutamate receptors and CAMs, are on-going.

Much less attention has been paid to the involvement of extracellular proteases in sleep-wake regulation. However, [@bib260] investigated mRNA expression of tPA and MMP-9, together with BDNF and the synaptic scaffolding protein Arc, before and after mice were sleep-deprived for 8 hours. They found that mRNA for tPA, BDNF, and Arc all increase in the cortex following sleep deprivation, while Arc mRNA levels increase in the hippocampus. Conversely, MMP-9 mRNA expression decreases in both the cortex and hippocampus after sleep deprivation ([@bib260]). They also found that increasing the ambient temperature, which increases REMS and SWS, decreases tPA, BDNF and Arc mRNA in the cortex and increases MMP-9 mRNA in the cortex and hippocampus. A microarray study ([@bib157]) also found increases in mRNAs for several MMP-interacting proteins in the cortex during sleep. Together, these results suggest a connection between sleep-wake state and these genes. It would be worthwhile to investigate how these changes in mRNA translate into changes in protein expression and proteolytic activity, and further, if any of these changes contribute to the increase in sleep propensity after sleep deprivation. In this context, however, it is interesting to note that female shift workers with poor sleep quality have higher levels of PAI-1, the primary inhibitor of tPA, in their blood compared to daytime shift workers ([@bib192]). Whether the increase in circulating PAI-1 is a negative feedback response to increased transcription of tPA mRNA after sleep deprivation is still yet to be determined.

One downstream product of both tPA and MMP-9 activity that is implicated in sleep regulation is BDNF. Previous work in rats shows that cortical injections of BDNF during sleep increase SWS, while injections of a polyclonal anti-BDNF antibody or the tyrosine kinase inhibitor K252a during wakefulness decrease SWS ([@bib73]). Also, increases in REM episodes induced by selective REMS disruption (RSD) positively correlate with increases in BDNF expression in the PPT and the subcoeruleus nucleus ([@bib51]). In a recent study ([@bib10]) two TrkB antagonists (K-252a and ANA-12) were injected into the PPT of rats prior to unrestricted sleep or RSD. The results show that RSD increases BDNF expression in the PPT, which is reduced when rats are pretreated with either K252a or ANA-12. Moreover, K252a injections in RSD animals reduce REMS episodes without changing the time spent in wakefulness. This implies that TrkB activation is necessary for the increase in REMS homeostatic drive. Along these lines, knockout of the truncated form of the TrkB receptor, which lacks a kinase domain, in mice leads to increased total REMS and decreased latency to REMS while SWS architecture is unaffected ([@bib278]). Interestingly, this form of the TrkB receptor is more highly expressed in astrocytes than neurons ([@bib76]).

Overall, these studies support the hypothesis that extracellular proteases play important roles within both the circadian and sleep-wake systems ([Fig. 2](#f0010){ref-type="fig"}, [Table 1](#t0005){ref-type="table"}). There is a paucity of information regarding the plasminogen pathway in the sleep-wake system relative to the circadian system, while both systems appear to be modulated by MMPs. The data suggest that one mechanism through which these proteases may act in both systems is through modulating BDNF signaling via TrkB receptors, although many other possibilities also exist. Given BDNF's importance in synaptic plasticity generally, and circadian rhythms and sleep-wake more specifically, it will be important for future studies to explore whether BDNF and/or other proteolytic targets serve as a link between these systems, what the role(s) of these downstream targets are in each system, and to what extent they are regulated by specific extracellular proteases in each of these systems.Fig. 2Extracellular proteases implicated in SCN circadian system (A) and sleep-wake system (B) modulation. For the sleep-wake system, note that the figure collates data from a variety of brain regions. The strength of the data in both systems varies, from simple mRNA or protein expression through extensive functional evidence. The figure does not attempt to represent all of the cell adhesion molecules, transmitters, or interactions that are known or theorized to participate in each system, but rather aims to illustrate the potential commonalities and differences between the systems.Fig. 2

3.4. Extracellular protease interacting proteins {#s0085}
------------------------------------------------

As discussed earlier, the extracellular proteases tPA, uPA and MMP can modulate cell signaling non-proteolytically by binding to membrane-localized receptors, including LRP-1 and annexin II ([@bib6], [@bib38]; [@bib271]). MMP-9 has also been shown to modulate cell signaling through cleaving cell-attached receptors, including β-dystroglycan, integrins, Eph-ephrin proteins, and neuroligin 1 ([@bib280], [@bib215]). Although most of these targets and subsequent intracellular signaling processes have not been investigated in the context of either circadian rhythm or sleep-wake regulation, our lab has explored the involvement of LRP-1 in circadian clock phase resetting.

### 3.4.1. LRP-1 {#s0090}

LRP-1 is a large protein that includes a 515 kDa extracellular α subunit that is non-covalently attached to an 85 kDa transmembrane β subunit ([@bib129], [@bib226]). LRP-1 has a diverse set of ligands, including apoE, tumor growth factor-β, MMPs, PAI-1, neuroserpin, tPA, uPA, and amyloid-β. Ligand binding can trigger endocytosis or activation of multiple protein kinases ([@bib129], [@bib226], [@bib271]). "Shedding" of the extracellular subunit generates a soluble protein that can continue to bind ligands, which can serve a sequestration/inactivation function ([@bib271]). This shedding can be mediated by a variety of extracellular proteases, including tPA, a variety of MMPs, ADAMs, and β-secretase 1 ([@bib271]), and the resulting soluble protein can interact with other receptors, including uPARs, NMDARs and platelet-derived growth factor receptors ([@bib226], [@bib271]). These receptor-LRP-1 interactions can generate functional changes linked to alterations in receptor localization. LRP-1 participates in LTP and learning and memory processes through mechanisms that involve tPA ([@bib129], [@bib298]). Evidence also suggests that, through its interaction with PSD-95, LRP-1 can regulate the surface expression of NR2B subunit containing NMDARs ([@bib160]).

LRP-1 could serve as a point of convergence for tPA, uPA, MMPs, and other regulators of the circadian clock, including NMDARs and BDNF/TrkB signaling. LRP-1 can both regulate and respond to the extracellular environment: via its endocytic activity it is able to control the levels of a variety of extracellular proteins, including tPA, uPA, vitronectin, PAI-1, and MMPs. Our lab has found that LRP-1 influences circadian clock phase shifting, as inhibiting LRP-1 abolishes glutamate-induced phase shifts of SCN neuronal activity rhythms *in vitro* ([@bib48]). While the mechanisms underlying these actions remain unclear, the data suggest that tPA is not required for LRP-1 to modulate circadian clock phase. However, because LRP-1 inhibits glutamate-induced phase shifts, we hypothesize that LRP-1's actions involve interactions with NMDARs and/or mechanisms downstream of NMDAR activation.

In summary, there has been minimal attention given to the potential involvement of receptors (and their intracellular signaling cascades) that interact with extracellular proteases in either the circadian or sleep-wake systems ([Fig. 2](#f0010){ref-type="fig"}, [Table 1](#t0005){ref-type="table"}). To the best of our knowledge, ours is the only investigation of LRP-1 in the SCN, and we are not aware of research investigating the function of LRP-1 in the sleep-wake system. Nevertheless, the microarray study by Mackiewicz (2007) found that LRP-1 mRNA expression increases in the cortex during sleep. In light of LRP-1's ability to endocytose numerous extracellular molecules and to modulate glutamatergic signaling, we believe continued exploration of LRP-1 in the circadian system, as well as an investigation of LRP-1 in the sleep-wake system, is warranted. We also believe investigating other extracellular protease-interacting receptors within the context of both systems would be worthwhile.

3.5. Astrocytes {#s0095}
---------------

Another critical facet of the extracellular environment is changes in astrocytic structure and signaling properties. Astrocytes exhibit structural dynamics that can involve interactions with the ECM, which result in volumetric and spatial changes in the extracellular space (ECS) and changes in the extent of neuronal appositions. Astrocytic morphological changes and how they modulate neuronal activity in the neuroendocrine system have been extensively investigated in the supraoptic nucleus, as recently reviewed ([@bib42]). However, similar changes have also been shown to occur in the hippocampus ([@bib206]), raising the possibility that they participate in learning and memory processes. Changes in astrocyte morphology have also been shown in the olfactory bulb in response to fasting and satiety signals ([@bib52]). Astrocytes also modulate brain processes, including those linked to learning and memory and to drug addiction, through releasing and responding to signaling molecules ([@bib16], [@bib229], [@bib166], [@bib140]). Their critical involvement in brain signaling through multiple mechanisms led to their inclusion within a 'tripartate synapse' functional unit together with pre- and post-synaptic neurons ([@bib216], [@bib77]).

Astrocytes contribute to the regulation of both the circadian and sleep-wake systems ([@bib7], [@bib231]). The mechanisms through which astrocytes participate in the two systems, however, are not fully understood. Some studies have focused on changes in astrocyte morphology, while others have investigated whether astrocytes interact with neuronal signals by actively secreting gliotransmitters. Regardless of the detailed mechanisms, these astrocytic processes are closely tied to changes in ECM, ECS and extracellular molecules. Here, we discuss the data linking astrocytes and the ECS in both systems.

### 3.5.1. Astrocyte morphology {#s0100}

Astrocytic morphology adjusts to changing physiological conditions by extending and retracting processes into and out of synaptic regions, which can dramatically alter the physical parameters of synaptic signaling, including synaptic cleft volume, the extent of neuron-neuron contact, the rate of astrocytic clearance of neurotransmitters and other substances from the synaptic cleft, and the degree to which substances can diffuse in and out of the synaptic active zone ([@bib207]). These structural changes involve interactions with the ECM and associated molecules ([@bib189], [@bib254]). In some cases, protein-protein interactions directly connect neurons and astrocytes. For example, EphA4-EphrinA3 connections have been identified between dendritic spines and astrocytic processes in the hippocampus ([@bib261]). Therefore, changes in astrocytic morphology may be both a consequence and a regulator of changes in ECM molecules.

Circadian rhythms in astrocytic morphology in the SCN have been studied for many years. The first demonstration of astrocyte circadian rhythms was in 1993, when daily changes in glial fibrillary acidic protein (GFAP) were found in the SCN of Syrian hamsters ([@bib143]). The distribution of GFAP immunoreactivity exhibits diurnal rhythms in both constant light and DD, moving from a distributed network pattern during the day to a condensed and isolated staining pattern at night. Together with several subsequent studies ([@bib244], [@bib68], [@bib187]) there is broad support for the existence of GFAP rhythms in the SCN, and because GFAP is essential for astrocytic cytoskeletal organization, they point to structural plastic changes in SCN cell networks ([@bib13]).

Astrocytes in the SCN undergo rhythmic structural rearrangements in addition to rhythms in GFAP. For example, there are day/night variations in glial and axonal terminal coverage on VIP neurons ([@bib13]). The data support a model where glial coverage of dendrites changes in a circadian manner: during the night glia tightly surround VIP dendrites and are retracted from VP dendrites, while in the day-time they move to cover VP dendrites more closely and retract from VIP dendrites. These rhythms in dendritic spine ensheathment may be important for gating photic signals ([@bib13], [@bib92]). Along these lines, it has been shown that changes in lighting conditions alters the ultrastructure of synapses formed by retinal ganglion cells in the SCN, primarily onto VIP neurons in the retinorecipient region ([@bib101]). VIP neurons have a greater number of synapses during the day than at night, and this includes both glutamatergic and non-glutamatergic synapses. For a more detailed review of the data supporting structural rearrangements of SCN synapses see ([@bib91]). Going forward, it will be important to determine to what extent these changes are driven by the circadian clock and/or external signals. Additional research is also needed to determine how these astrocytic morphological changes affect the signaling properties of the neurons.

Differences in astrocytic morphology are also seen between sleep and wake states. Sleep deprivation induces morphological changes in cortical astrocytes, most notably an extension of their filipodial appositions into the synaptic space ([@bib15], [@bib7]). As with the circadian system, the effects of changing astrocytic morphology on sleep may include changes in neuronal ensheathment. Mice exposed to acute or chronic sleep deprivation display increases in perisynaptic astrocytic processes that surround spine heads, axons, and dendrites ([@bib15]). These processes exhibit signs of enhanced astrocytic phagocytosis, and the astrocytes contain more endosomes, a canonical indication that cells are participating in cellular or metabolic recycling ([@bib14]). Functionally, these astrocytic dynamics may contribute to the reduction or "scaling down" of synaptic size and connections during sleep that has been seen by other research groups ([@bib53], [@bib58]). Thus, similar to the circadian system, astrocytic morphological changes are seen with changes in sleep-wake state, but the functional role(s) of these changes remain obscure.

Although the precise mechanisms through which these rearrangements are propagated and what role they play remains unclear, these daily iterative structural changes are reminiscent of ECM-associated events seen during development, which suggests that these processes could involve ECM remodeling. Changes in cell-attached proteins also likely participate in regulating these changes. For example, astrocyte morphology changes in the hippocampus have been shown to involve connexin proteins ([@bib206]) and a protease-activated receptor ([@bib257]), while in the hypothalamic neuroendocrine system they involve local neuromodulators and changes in the cell adhesion protein SynCAM (reviewed in [@bib42]. Many questions remain regarding how changes in astrocyte morphology modulate the circadian and sleep-wake systems, including: What cellular and molecular processes drive these changes, and what are the mechanisms through which changes in astrocyte morphology influence circadian and sleep functions? For example, changes in astrocyte morphology could affect synaptic signaling through altering the buffering capacity and/or tortuosity of the ECS. In some brain regions, astrocytes can control the concentration of extracellular glutamate through a variety of mechanisms ([@bib161]).

Astrocytic regulation of the ECS has not been investigated in the circadian system, but it has become a focus in the sleep-wake system. In the cortex, the transition from wakefulness to sleep is correlated with an increase in ECS volume that appears to alter the diffusion properties of molecules in the ECS ([@bib289]). Sleeping mice or mice that are anesthetized exhibit a 60% increase in interstitial space in the cortex, which is associated with a higher clearance rate of molecules and metabolites from the brain, possibly due to a higher exchange rate of cerebrospinal fluid. In support of this idea, the clearance of radio-labeled amyloid-β is faster in sleeping vs. awake mice ([@bib289]). Similarly, sleep deprivation increases morning amyloid-β levels in blood plasma of humans, and this increase is correlated with a decrease in expression of soluble LRP-1 ([@bib279]). Because LRP-1 mediates the internalization of amyloid-β, this finding suggests that LRP-1 dependent regulation of extracellular molecules may be closely tied to the processes regulating sleep ([@bib127]). Given the evidence of an interaction between amyloid-β accumulation and sleep disruptions (reviewed in [@bib123], it is possible that one critical function of sleep is to increase ECS and allow enhanced clearance of toxic metabolites.

Other research found that application of the β-adrenergic agonist isoproterenol to cortical brain slices decreases ECS volume and increases the volume of distal astrocytic processes ([@bib247]). Functionally, the authors concluded that β-adrenergic activation during wakefulness increases astrocyte extensions into the synaptic space, decreasing ECS and increasing the concentration of extracellular substances. A recent review ([@bib224]) highlights evidence that changes in astrocytic structure during sleep can alter neuronal communication through changing the ECS, possibly involving a glial-lymphatic, or 'glymphatic', system and its ability to change the ionic and/or small molecule synaptic composition. It is important to note, however, that the theory of a 'glymphatic' system for clearing toxic metabolites is not universally accepted (e.g., [@bib252]). Moreover, a recent study ([@bib84]) found that anesthesia decreases the rate of CSF clearance in mice relative to that seen during wakefulness. Importantly, this study did not investigate CSF clearance rates during sleep, which is a critical next step.

Taken together, these studies support astrocytic regulation of ECS clearance being an important aspect of sleep processes. It will be interesting for future research to determine whether astrocytic modulation of the ECS functionally regulates sleep-wake state transitions or whether it is a result of those transitions. It will also be important to investigate the role of other mechanisms in regulating ECS clearance. For example, ([@bib96]) recently showed that enzymatic degradation of the ECM can dramatically alter the shape and diffusion dynamics of the ECS.

### 3.5.2. Gliotransmission {#s0105}

Another mechanism through which glia can influence neuronal plasticity is by releasing signaling molecules (e.g., [@bib102]; [@bib100]; [@bib229]), and these gliotransmitters appear to affect both circadian and sleep-wake systems. In reviewing the evidence for gliotransmission, it is important to note that gliotransmitter (and neurotransmitter) signaling efficacy can vary dramatically with changes in astrocyte morphology and its interactions with the ECM ([@bib16]), and the interplay between these variables has received little attention in either system.

Recent evidence that astrocyte-derived signals are important for circadian rhythms comes from three studies. One group used astrocyte-specific *Bmal1* knockout mice and casein kinase-1ε mutant mice to show that astrocytes regulate the free-running period of clock gene expression rhythms in the SCN and behavioral locomotor activity rhythms ([@bib266]). Similarly, a second group showed that selective ablation of *Bmal1* in astrocytes alters behavioral rhythms that can be rescued through pharmacological manipulation of GABA signaling ([@bib9]). Addressing the question of how astrocytes communicate with neurons, a third group used live cell imaging to demonstrate that neurons and astrocytes have rhythms in intracellular calcium that are in antiphase to one another, with neurons being metabolically more active during the circadian day and astrocytes more active during the night. Additionally, they demonstrated that glutamate functions as a gliotransmitter in this system: night-active astrocytes release glutamate, which activates presynaptic NR2C subunit-containing NMDARs. This stimulates GABA release, leading to decreased neuronal activity in the SCN at night ([@bib25]). In light of previous work showing that astrocytes in the SCN exhibit periodic (7-20 second) oscillations in intracellular Ca^2+^ that are inhibited by glutamate ([@bib269]), it will be interesting to investigate potential mechanistic connections between astrocytic Ca^2+^ rhythms and glutamate release in the SCN. The research by [@bib25] highlighting the importance of gliotransmission in the SCN is consistent with evidence that a variety of astrocytic signals, including nitric oxide (NO), ATP, adenosine, and the cytokines TNFα and IL1, influence both circadian and sleep-wake systems. Although many of these molecules have intracellular functions, we wish to focus here on their potential extracellular actions.

#### 3.5.2.1. Nitric oxide {#s0110}

NO has been implicated as an extracellular modulator of photic transduction in the SCN ([@bib60], [@bib97], [@bib218]). Nitric oxide synthase (NOS) is found in SCN astrocytes ([@bib31]), supporting astrocytes as one source of NO in the SCN. Notably, treating SCN brain slices with hemoglobin, an extracellular NO scavenger, disrupts some but not all actions of NO in the SCN ([@bib8]), suggesting that NO participates in both intracellular and transcellular signaling in the SCN.

Signaling by NO also modulates the sleep-wake system. Generally, during wakefulness and early stages of sleep deprivation, the activity of NOS increases, resulting in NO production and sleep promotion ([@bib283]). Importantly, NO affects both REMS and SWS processes (summarized in [@bib28]) and the effects vary by cell type. The cell type differences could be due in part to production of NO by distinct isoforms of NOS, neuronal NOS (nNOS) vs. inducible NOS (iNOS), the latter of which being predominantly expressed by microglia and astrocytes ([@bib191], [@bib286]).

In their genetic screen, [@bib157] identified *Nos3* as one of the genes that increases in the cerebral cortex during sleep. Consistent with this finding, another study found that cortical interneurons co-expressing nNOS and the substance P receptor NK1 exhibit increased c-Fos expression during sleep ([@bib185]). Also, *nNOS* knockout mice display a decrease in slow wave activity during sleep, indicating a decrease in sleep homeostatic drive, but they also have a shorter latency to sleep, which implies that sleep homeostatic drive increases ([@bib185]). A commentary on this report suggested that nNOS regulates sleep through two distinct pathways; one in response to arousal and the other associated with sleep homeostasis ([@bib98]). Exploring this relationship further, the same group found that the amount of time spent in SWS does not alter the minimal amount of c-Fos activity in one population of nNOS/NK1 neurons, while another population of nNOS/NK1 neurons exhibits increased c-Fos expression after sleep deprivation ([@bib62]). Together, these findings reinforce the idea that the role of NO in sleep regulation is cell-type dependent, and that there are at least two distinct roles of nNOS neurons in sleep. Although these studies focused on neuronal actions of NO, the NO can diffuse to and communicate with nearby astrocytes to regulate sleep processes in a manner that would be affected by changes in the ECS ([@bib135]). Moreover, as mentioned above, NO synthesized by glial cells may also modulate sleep. In support of this, injecting a specific inhibitor of nNOS into the basal forebrain decreases REMS recovery in sleep-deprived mice, while injecting a specific inhibitor of iNOS prevents SWS recovery ([@bib125]).

#### 3.5.2.2. Purines {#s0115}

ATP and adenosine are other potential gliotransmitters modulating the circadian and sleep-wake systems. Although ATP released into the extracellular space can be rapidly degraded to adenosine, it is a signaling molecule in its own right, particularly with respect to signaling between astrocytes and neurons ([@bib237], [@bib276]). ATP activates purinergic receptors, generally enhancing cellular (neuronal and astrocytic) activity. Conversely, adenosine (either released from cells or after extracellular degradation from ATP) activates distinct adenosine receptors that can either increase or decrease neuronal activity ([@bib209], [@bib256], [@bib110]). Astrocytes and neurons both release ATP and adenosine ([@bib210], [@bib75], [@bib110]), although astrocytes may be the primary source for released adenosine ([@bib20]).

Genes involved in ATP regulation exhibit circadian oscillations in the SCN ([@bib170]). Circadian oscillations in ATP production and extracellular accumulation have been observed *in vitro* in SCN2.2 cell cultures (which may be comprised largely of astrocytes), and daily variations in extracellular ATP occur in rat SCN *in vivo*. Interestingly, these oscillations are also seen in cortical astrocyte cultures, indicating that ATP extracellular accumulation may be a pervasive physiological output of circadian oscillating cells ([@bib285]). Other research has demonstrated that adenosine, acting on A~1~ receptors, can phase shift the SCN circadian clock ([@bib5]) and inhibit photic phase shifts of the SCN clock ([@bib277], [@bib69], [@bib249]). The inhibition of photic phase shifts may involve blocking presynaptic glutamate release ([@bib277], [@bib104]). Not clear from these studies, however, is the source of the adenosine and the mechanisms regulating adenosine (or ATP) release.

With respect to the sleep-wake system, ATP and adenosine are well-known sleep regulatory substances ([@bib43], [@bib18], [@bib110]). ATP release from cells is thought to involve pannexin-1 channels ([@bib156]). Knockout mice that lack this channel display an inverted waking/SWS ratio and are more active in both light and dark periods ([@bib131]). The extracellular actions of ATP also include affecting sleep homeostasis and recovery from sleep deprivation. First, stimulation of purine type 2 (P2) receptors by an ATP agonist can increase SWS in mice. Additionally, P2X7 receptor expression varies with sleep state, and sleep deprived mice lacking P2X7 receptors exhibit decreased recovery sleep responses ([@bib136]). These data support direct actions of extracellular ATP on sleep-wake processes in addition to those described below that are exerted by it metabolic product, adenosine.

Knockout mice lacking the 5\'-ectonucleotidase enzyme CD73 required to convert AMP to adenosine exhibit increased SWS after sleep deprivation as compared to control mice ([@bib300]). Adenosine enhances sleep in part through activating A~2a~ receptors that inhibit the activity of wake-promoting neurons ([@bib112], [@bib135], [@bib217]). Astrocyte-derived adenosine can also modulate sleep through activating A~1~ receptors ([@bib103]). This group found that blocking gliotransmission reduces slow-wave activity and results in a decrease in sleep pressure. Moreover, they found that the sleep suppressing effects of an A~1~ receptor antagonist are prevented by blocking gliotransmission ([@bib103]). Research also supports adenosine released by astrocytes as being important for sleep-wake regulation ([@bib20]). The effects of adenosine are complex, however, since increases in glucose, which would be considered a signal of increased rather than depleted energy stores, can stimulate astrocytic release of adenosine in the VLPO of mice ([@bib238]). Interestingly, this study also showed that the glucose-induced increase in adenosine release was significantly greater in tissue collected at the beginning of the sleep period than the beginning of the activity period. It will be important in future studies to determine whether the circadian clock regulates this difference or if it is solely a result of differential sleep pressure.

Together, these data indicate that sleep homeostasis depends on both ATP and adenosine, with glial cells being a prominent source of both signaling molecules. The data also support adenosine and ATP playing important regulatory roles in the circadian system. Finally, there is tantalizing evidence for interactions between the two systems that involve extracellular purine signaling. Moving forward, it will be important to clarify the source(s) of both ATP and adenosine in both systems, what stimulates their release, and how changes in the extracellular environment (e.g, the availability of enzymes to convert ATP to adenosine; proximity of astrocytes to the synaptic active zone; ECS tortuosity) modulate their signaling capabilities.

#### 3.5.2.3. Cytokines {#s0120}

Other potential gliotransmitters acting within the circadian and sleep-wake systems include cytokines such as TNFα, IL1β, and IL6. Cytokines are active in the periphery of the body, in blood plasma and in CSF, and cytokines produced in the periphery can cross the blood brain barrier and stimulate brain cells to release more cytokines and initiate additional immune responses (see Capuron and Miller et al., 2011 for review). Within the brain, cytokines can be released by neurons, astrocytes and microglia ([@bib290], [@bib142]). Cytokine release into the extracellular space not only initiates or exacerbates immune responses by recruiting monocytes to the brain ([@bib49]), but it also modulates synaptic plasticity associated with hippocampal learning and memory and drug addiction through multiple mechanisms ([@bib166], [@bib140]). Cytokines can regulate membrane-localized molecules as well. For example, astrocyte-derived TNFα modulates hippocampal synaptic strength in part through increasing AMPAR surface expression ([@bib255]). Another study found that TNFα is released from astrocytes in the hippocampus in an activity dependent manner and it regulates β3-integrin and N-cadherin expression in neurons ([@bib40]). Similarly, a TNFα receptor has been shown to modulate N-cadherin expression in hippocampal neurons ([@bib138]).

A bidirectional link between the immune system and circadian rhythms is well established in regards to both peripheral clocks and the central clock. For example, there are circadian rhythms in basal plasma TNFα, IL1β, IL6 and the IL6 receptor (IL6R) in humans, although the source of these proteins is not known ([@bib12], [@bib24], [@bib274], [@bib273]). There are also circadian rhythms in immune responses ([@bib46], [@bib155], [@bib239]). In the reverse direction, peripheral injection of lipopolysaccharide (LPS; an endotoxin serving as an immune challenge) induces phase shifts of locomotor activity rhythms in mice ([@bib202]) that involve TNFα-dependent mechanisms within the SCN. TNFα and IL1β can decrease expression of *Per* and *Cry* genes in fibroblast and neuronal cell cultures and in the liver by inhibiting BMAL-CLOCK transcriptional activity, and they decrease the behavioral activity of mice when administered during their active phase ([@bib32], [@bib86]). These effects may involve the transcriptional regulator *Twist1* ([@bib168]). On the other hand, a separate study found that cell culture media collected after TNFα treatment, but not after IL1β treatment, increases *Per1* expression in fibroblasts ([@bib64]). While the evidence for circadian-immune system interactions is extensive (see [@bib46]; [@bib239]; [@bib35] for reviews), here we will focus primarily on the potential role of cytokines functioning as gliotransmitters to modulate the circadian clock.

Microglia isolated from hippocampus exhibit day/night rhythms in TNFα and IL1β mRNA and immune reactivity, with higher levels in the day than the night ([@bib80]), but whether these cytokines are acting as intercellular signaling molecules is not clear. Similarly, mRNA transcripts of both TNFα and IL1β in the hypothalamus exhibit diurnal expression that is highest during the light phase ([@bib26], [@bib259], [@bib34]). Moreover, administration of TNFα reduces expression of *Dbp* mRNA*,* a circadian regulated transcription factor, in SCN tissue ([@bib32]). Finally, another study found that TNFα application shifts PER2 expression rhythms in SCN astrocyte cultures, and these cultures increase secretion of inflammatory markers CCL2 and IL6 in response to TNFα application ([@bib202]). Moreover, TNFα receptor mRNA levels are rhythmic in the SCN, with higher levels at night, and TNFα receptor knockout mice exhibit significantly longer free-running periods compared to wildtype mice ([@bib202]). While suggestive, more research on cytokine signaling in the SCN is needed. Also, investigating interactions of these cytokines with cellular adhesion molecules or extracellular proteases specifically in the SCN will be important in elucidating the extent to which cytokines participate in the extracellular regulatory mechanisms of the circadian clock.

Cytokines have been studied far more extensively in the context of sleep regulation, and there are excellent reviews of the accumulated data ([@bib114], [@bib120], [@bib43], [@bib299], [@bib134], [@bib117]). Substantial research has focused on the intersection between the sleep and immune systems in terms of how inflammatory responses can enhance sleep and how sleep disruption can exacerbate immune responses ([@bib50], [@bib200], [@bib117], [@bib290]). In addition to modulating each other, these interactions can significantly affect neuronal processes. For example, increases in circulating cytokines due to surgery or sickness can elicit the negative symptoms that occur in response to sleep loss or circadian dysregulation, including fatigue and impaired cognition and memory, and these effects are mimicked by administering exogenous cytokines ([@bib43], [@bib299]). Similarly, memory impairments caused by sleep fragmentation or surgery are accompanied by increases in TNFα mRNA expression, and the mRNA changes but not the memory deficits are exacerbated when surgery is either preceded or followed by sleep fragmentation ([@bib267]). However, for the purposes of this review, we will focus more directly on evidence that cytokines such as TNFα and IL1β and IL6 function as signaling molecules in the brain that regulate sleep homeostasis under physiological conditions.

As reviewed extensively, ([@bib133], [@bib134], [@bib114], [@bib117]) TNFα and IL1β protein and mRNA generally increase during wakefulness and decrease during sleep. Inhibiting their activity or expression decreases both SWS and REMS, while administering these proteins can induce long-lasting sleep (primarily SWS), even at doses that don't elicit fever. They do not affect all sleep stages uniformly. Thus, low doses of both cytokines selectively increase SWS, at moderate levels they increase SWS and decrease REMS, and at even higher levels they inhibit both SWS and REMS ([@bib134], [@bib56]). It is also noteworthy that TNFα and IL1β appear to affect sleep slightly differently across the circadian cycle. Mice lacking IL1β receptors have less SWS and REMS during their active period with no changes during their sleep period, while mice lacking TNFα receptors have decreases in SWS and REMS primarily during the end of their active period and throughout their sleep period ([@bib71], [@bib72]).

One important question when exploring the central actions of cytokines on sleep is whether the cytokines are derived from the periphery or the brain. As reviewed elsewhere ([@bib50], [@bib200]), peripherally derived inflammatory processes can signal the brain through a variety of pathways, including neural stimulation as well as through cytokines entering the brain. Nevertheless, we know that neurons and glial cells in cortical, brainstem and hypothalamic sleep regulatory regions express IL1β, TNFα and/or their receptors (see [@bib117]), and that these cytokines modulate neuronal activity in all these regions. Moreover, the effects of cytokines on sleep are cell-type specific. For example, when IL1β receptors are expressed solely in either astrocytes or neurons mice have more spontaneous REMS, their SWS exhibits enhanced delta power, and they have more consolidated sleep after short-term sleep deprivation. However, when IL1β receptors are only expressed in neurons, SWS after sleep deprivation has reduced delta power, supporting the need for astrocytic ILβ signaling in normal sleep homeostasis ([@bib116]). Intriguingly, this same study found that restricting IL1β receptor expression to either neurons or astrocytes prevents induction of IL1β and IL6 in the hypothalamus after IL1β administration and it prevents ILβ-induced increases in sleep and body temperature. Moreover, the REMS suppression induced by peripheral LPS injections is reduced in mice expressing IL1β receptors in neurons vs. those expressing IL1β receptors in astrocytes ([@bib115]). Together, these data suggest that IL1β receptor expression in both neurons and astrocytes is needed for normal cytokine actions on sleep, and that additional cells in the brain, such as endothelial or microglial cells, are important for IL1β's sleep-inducing actions, especially regarding its actions within the hypothalamus.

Several studies have specifically investigated astrocyte and microglia involvement in cytokine regulation of sleep. Both astrocytes and microglia become activated after sleep loss and can release cytokines in multiple brain regions ([@bib253], [@bib99], [@bib275], [@bib15], [@bib14]). In the hippocampus, 5 days of sleep deprivation increases the expression of GFAP and compliment type 3 receptors, which are indicators of activated astrocytes and microglia, respectively ([@bib111]). Focusing specifically on microglial involvement, inhibiting microglia with minocycline can prevent rebound SWS and REMS in mice after sleep deprivation ([@bib281]), and minocycline administration to mice experiencing 48 hours of sleep deprivation decreases the cognitive impairments associated with sleep loss ([@bib275]). Another study found that mice with a constitutive deletion of toll-like receptor-4 which facilitates production of pro-inflammatory cytokines and is highly expressed in microglia and astrocytes ([@bib106]), exhibit lower levels of REMS across the entire day and have higher levels of sleep specifically during the beginning of the wake period. They also exhibit less rebound sleep after mild sleep deprivation, suggesting an overall lower sleep drive ([@bib282]). On the other hand, a variety of studies have shown that astrocytes can release both IL1β and TNFα in response to extracellular ATP ([@bib134], [@bib120]). Moreover, acute sleep loss of 8 hours induces astrocytic phagocytosis of neuronal synapses in the frontal cortex of mice, while activation of microglia in the same brain region only occurs after chronic sleep loss of over 4.5 days ([@bib14]). These results suggest that structural changes occur during sleep loss, as indicated by astrocytic phagocytosis of synapses, and that they may be a result of cytokine activation.

Focusing on local cell networking, mixed astrocyte/neuron cortical cell cultures exhibit bursting activity, membrane oscillations, and slow-wave power changes consistent with changes in sleep state ([@bib121]). Electrical stimulation decreases these neuronal activity parameters, with rebounds in their expression 24 h later. Adding TNFα to the cultures induces the opposite effects, and these TNFα-induced changes are reversed by electrical stimulation. A more recent study ([@bib220]) investigated astrocyte involvement *in vivo*. Using a combination of optogenetics and calcium imaging, they found that both spontaneous and induced increases in cortical astrocytic intracellular Ca^2+^ are immediately followed by rapid spikes in extracellular glutamate and a switch from fast (desynchronized) to slow (synchronized) oscillations in local field potentials, consistent with the onset of a SWS-type state. Together, the data from these studies are consistent with the idea that sleep states are an emergent property of local cell networks that rely on tightly regulated interactions between neurons and glial cells that include cytokine signaling.

Although most research on cytokine modulation of sleep homeostasis has focused on TNFα and IL1β, IL6 also participates in this process ([@bib50], [@bib117]). However, IL6 signaling is complex. As reviewed recently ([@bib230]), "classical signaling" involves IL6 binding its membrane bound receptor (IL6R), which then binds to and stimulates dimerization of gp130 receptors, leading to activation of intracellular signaling processes. This form of signaling is somewhat restricted in the brain because IL6Rs are only expressed by microglia. However, the extracellular proteases ADAM10 and 17 can cleave IL6Rs to generate a soluble form (sIL6R). IL6 binding to sIL6R can then activate gp130 receptors on neighboring cells via "trans-signaling". Because multiple cell types throughout the brain express gp130 receptors, this suggests that trans-signaling by IL6 is more widespread than classic signaling in the brain. Notably, this 'trans' signaling is similar to the 'shedding' of the extracellular subunit of LRP-1 discussed earlier, which expands its potential locus of interaction.

In this context, it is also important to note that ADAM17 was originally identified as the enzyme that cleaves and activates TNFα, and thus is also called TNFα converting enzyme (TACE) ([@bib234], [@bib293]). In fact, there is a large literature showing that ADAM10 and 17 as well as several other MMPs have reciprocal regulatory roles within the peripheral and central immune systems ([@bib234], [@bib293]). Although a thorough discussion of these interactions is outside the scope of this review, the data warrant more attention being given to their potential intersections with sleep homeostatic regulation.

The mechanisms through which cytokines modulate neuronal activity and *vice versa*, how neuronal activity modulates cytokine activity, likely involves multiple signaling processes. Cytokines can modulate the signaling of many neurotransmitters, including serotonin, glutamate, acetylcholine and GABA. However, these interactions are outside the scope of this review, and interested readers are directed towards other excellent reviews ([@bib50], [@bib114], [@bib117]). More relevant to this review, neuronal activity likely alters cytokine expression and activity within the context of sleep homeostasis through mechanisms that involve a complex interaction between cytokines, purines, and NO. One model that has been put forward is based in part on extensive data (some reviewed in the previous sections) showing that increases in extracellular NO, ATP and adenosine accompany wakefulness/increased neuronal activity ([@bib133], [@bib134]). ATP stimulation of P2X7 receptors can increase TNFα and IL1β activity and release. TNFα and IL1β in turn can stimulate NFkB to translocate into the nucleus where it can increase adenosine receptor expression. Additionally, NFkB can indirectly increase release of NO, prostaglandin and adenosine. Increases in all of these molecules contribute to inhibiting local neuronal activity. These interactions would alter neuronal activity at the level of local circuits, which could be modulated more globally by sleep regulatory centers.

In summary, the evidence indicates that cytokines are important players in maintaining sleep homeostasis, and they may serve as reporters of sleep disturbances. Moreover, it is likely that they act in coordination with NO and purines, all of which could be produced by glial cells. Although the importance of cytokines in sleep homeostasis is clear, more research is needed to parse out the precise role of astrocyte-, microglia-, and neuron-derived cytokines in the sleep-wake system, and what other cells might be involved. For example, the data on mice with selective expression of IL1 receptors in either astrocytes or neurons ([@bib116]) suggest that the actions of IL1 involve additional cells within the brain. We also do not know the extent to which other extracellular molecules modulate the actions of cytokines with respect to sleep homeostasis. The complex signaling by IL6 and its regulation by the extracellular proteases ADAM10/17 is just one example of this type of interaction. Finally, it will be important to clarify the intersecting mechanisms through which the circadian and sleep-wake systems regulate cytokines in the brain.

Taken together, it is evident that astrocytes are key regulators of both the circadian and sleep-wake systems ([Fig. 3](#f0015){ref-type="fig"}, [Table 1](#t0005){ref-type="table"}). Their mechanisms of action likely involve a complex interplay between altering the physical structure of the ECS, releasing signaling molecules and modulating the composition of the ECM. However, much of this remains speculative as few circadian or sleep studies have directly assessed interactions between astrocytes and the ECM and their functional implications. A better understanding of these interactive processes within each system is a critical area of exploration.Fig. 3Astrocyte-associated molecules and mechanisms implicated in SCN circadian system (A) and sleep-wake system (B) modulation. For the sleep-wake system, note that the figure collates data from a variety of brain regions. The strength of the data in both systems varies, from simple mRNA or protein expression through extensive functional evidence. The figure does not attempt to represent all of the astrocyte-linked mechanisms known or theorized to participate in each system, but rather aims to illustrate the potential commonalities and differences between the systems.Fig. 3

4. Conclusions and questions {#s0125}
============================

Secreted molecules interacting in the extracellular space influence neuronal processing in various regions of the nervous system. Despite the crucial role that the ECM and interacting molecules play in a variety of brain functions, they remain largely understudied and poorly understood in most systems, with circadian and sleep-wake regulation being no exception. The evidence presented here demonstrates that these extracellular molecules can dramatically influence the functioning of both systems. Although the precise mechanisms have not been elucidated, one unifying concept to consider is that the sleep-wake and circadian systems integrate processes on a relatively slow timescale (hours vs. seconds or minutes) that doesn't directly equate to the rapid synaptic signaling mechanisms of neurotransmitters. In contrast, the interactions occurring within the extracellular space, including structural changes, proteolytic processes, and ECM remodeling, generate changes in cell signaling that can integrate over longer time spans. Thus, their importance within the circadian and sleep-wake systems may lie in their ability to sense the rapid synaptic signaling events and transform them into broader changes in cell/network activity consistent with the daily changes orchestrated by both systems.

[Table 1](#t0005){ref-type="table"} summarizes many of the components of the extracellular environment that have been linked to the circadian and sleep-wake systems. However, our understanding of how these molecules work within these two systems still is largely superficial. Moreover, most extracellular molecules have not yet been studied, or have been studied primarily in one system or the other. Some of important questions that remain unanswered include: How do these proteins interact to influence each system? How pervasively does the ECM influence cell signaling in these systems? How do the expressions and actions of these molecules change over the course of a lifetime or in response to diseases or other disruptions? Although there is evidence that some of these extracellular processes are shared by other brain systems (e.g., the limbic and neuroendocrine systems), it is likely that each region utilizes a unique subset of these processes, and it will be important to clarify their different combinations and the functional consequences of these combinations associated with the circadian and sleep-wake systems. Additionally, in many cases it is not clear whether these extracellular processes are *regulators* or *consequences* of state changes generated by the two systems. Another major question is the extent to which microglia participate in these two systems. A role for microglia linking the immune and sleep systems is strong, but information on microglia in the SCN circadian system is scant. An additional complication stems from the heterogeneous nature of all the brain areas involved in these two systems. It will be imperative moving forward to better characterize the extracellular interactome of different cell types in each area. Along these lines, a recent paper used single-cell RNAseq to phenotype the transcriptome of 6 different populations of cortical GABAergic neurons ([@bib211]). Intriguingly, differential expression of CAMS was one of the 6 categories of genes that distinguished these groups of neurons.

Lastly, when comparing the research from each of these two fields, it seems apparent that each can learn from the other. For example, the data on changes in ECS being critical for sleep-wake processes suggests that similar effects might be occurring in the SCN. Cytokine signaling has also been studied far more extensively in the sleep-wake system than the circadian system. Conversely, the involvement of extracellular proteases and their downstream targets in regulating circadian phase resetting suggests that more attention to these proteins in the sleep-wake system is warranted. While we do not propose that the ECM, extracellular proteins and glial processes will provide all the answers needed to completely understand the circadian and sleep-wake systems, we are confident that neither system will be fully understood without fully exploring these dynamic extracellular processes.
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